Data presented at the 2024 FMF (Fetal Medicine Foundation) World Congress in Lisbon, Portugal shows the potential for a n automated system to deliver genomic profiles of fetal cells that is highly concordant with the genomic analysis obtained from invasive procedures. Results of a large clinical validation study show that Menarini Silicon Biosystems' fetal cell based noninvasive prenatal screening (NIPT) technology can accurately detect both fetal genome-wide pathogenic copy number variants greater than 600Kb in size and the commonly screened trisomy conditions. BOLOGNA, Italy and HUNTINGDON VALLEY, Pa.
, July 2, 2024 /PRNewswire/ --The Reproductive Precision Medicine Unit of Menarini Silicon Biosystems (MSB) presented last week, at the 21 st World Congress of the Fetal Medicine Foundation meeting in Lisbon, Portugal , results of a large multicenter study describing their next generation non-invasive prenatal testing technology using fetal cells isolated from maternal blood. The genomic analysis of these fetal cells showed a high concordance with the analysis of fetal cells obtained from invasive diagnostic procedures. Moreover, MSB's cell-based test, under development, demonstrated its potential validity for screening genomic conditions not easily found with currently available, state of the art, non-invasive screening technologies based on cell-free DNA (cfDNA) analysis.
This large study, which enrolled over 1,000 women, was centered on isolating individual fetal (trophobla.
